GOSSHIGH SIGNALRISK10-K

GOSS has pivoted from pursuing Phase 3 trial completion to damage control mode following disappointing PROSERA study results, with revenue substantially declining and the company now focused on salvaging regulatory pathways.

The language changes reveal a fundamental strategic shift from confident advancement toward regulatory approval to seeking "regulatory alignment" and evaluating "strategic options" - clear indicators that the Phase 3 PROSERA results fell short of expectations. The company is now in a reactive posture, prioritizing FDA feedback sessions and capital structure strengthening rather than commercial preparation.

Comparing 2026-03-17 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

The financial deterioration reflects the clinical setback, with revenue declining substantially year-over-year while current liabilities increased 41%. Total assets contracted significantly from $315.3M to $172.2M, and current assets fell similarly to $167.6M, though cash declined more modestly to $37.7M. The overall financial picture suggests meaningful cash burn and asset consumption during a challenging period for the company's primary development program.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-57.7%
$114.7M→$48.5M

Revenue declined 57.7% — significant demand weakness or market share loss warrants investigation.

Current Assets
Balance Sheet
-45.9%
$309.9M→$167.6M

Current assets declined 45.9% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-45.4%
$315.3M→$172.2M

Total assets contracted 45.4% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
+40.9%
$45.0M→$63.4M

Current liabilities surged 40.9% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-18.1%
$46.1M→$37.7M

Cash decreased 18.1% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-13
ADDED
As of March 10, 2026, the registrant had 234,696,281 shares of common stock ($0.0001 par value) outstanding.
Our Strategy Our near-term strategy is to focus our resources on advancing seralutinib for the treatment of PAH and to pursue regulatory alignment and potential approval as efficiently as possible.
Based on the totality of data from the Phase 3 PROSERA Study and the Phase 2 TORREY Study, including general consistency across endpoints and within higher risk subgroups, we believe seralutinib demonstrates a risk benefit profile that supports continued regulatory dialogue.
Following our February 2026 announcement of topline results from PROSERA, we are prioritizing (i) completing in-depth analyses of the PROSERA dataset, (ii) engaging with the U.S.
Food and Drug Administration, or FDA, to obtain feedback regarding potential regulatory paths forward, and (iii) evaluating our strategic options and resource allocation as a company, in addition to strengthening our capital structure.
+7 more — sign up free →
REMOVED
As of March 6, 2025, the registrant had 227,221,261 shares of common stock ($0.0001 par value) outstanding.
Richard Aranda, M.D., our Chief Medical Officer, is an experienced clinician and drug developer with previous experience at Bristol Myers Squibb Company, Novo-Nordisk, Inc., Receptos and Celegene Corporation.
Our Strategy We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of PH.
Critical components of our business strategy include: Complete the ongoing Phase 3 PROSERA Study of seralutinib in PAH and pursue regulatory approval.
We commenced the registrational Phase 3 PROSERA Study in PAH in the fourth quarter of 2023.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →